drugset / Trial / NCT02928978
Ruxolitinib for Premalignant Breast Disease
Phase 2
Completed
84 enrolled
Julie Nangia
Incyte Corporation · collabTranslational Breast Cancer Research Consortium · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Timeline
- Start
- 2018-05-13
- Primary completion
- 2024-08-29
- Completion
- 2024-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |